Effect of diabetes on clinical efficacy of hepatic arterial chemoembolization in the treatment of non-hepatitis virus hepatocellular carcinoma
10.3760/cma.j.issn.1005-1201.2017.01.012
- VernacularTitle:糖尿病对肝动脉化疗栓塞治疗非肝炎病毒肝细胞肝癌临床疗效的影响
- Author:
Xuegang YANG
;
Shi ZHOU
;
Ge WU
;
Zhengwen LI
;
Yanyuan SUN
;
Huachang WEN
;
Hui WU
;
Rong CAO
;
Yongjun WEN
;
Guohui XU
- Keywords:
Diabetes mellitus;
Carcinoma,hepatocellular;
Chemoembolization,therapeutic;
Prognosis
- From:
Chinese Journal of Radiology
2017;51(1):53-57
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of diabetes on clinical efficacy of transcatheter arterial chemoembolization (TACE) in the treatment of non-viral hepatitis hepatocellular carcinoma (HCC). Methods Retrospectively analyzed the clinical data of 367 non-hepatitis virus HCC patients treated by TACE, included 153 diabetes mellitus cases (test group) and blood glucose of 214 patients was normal (control group). To assess the treatment effect after 1 month of TACE based on response evaluation criteria in solid tumors, include complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), and calculate the disease control rate. Through 6 to 75 months follow-up to observed long-term efficacy, record the time to progression (TTP) and overall survival (OS) time. Survival rate were analyzed using Kaplan-Meier method and Log-rank analysis by SPSS 16.0. The single-factor analysis was used to analyze variables which variables that differed were analyzed by Cox regression. Results The disease control rate of test group was 69.9%(107/153) and control group was 74.3%(159/214), the difference was no statistically significant (P=0.125). The median time to progression (mTTP) and median overall survival (mOS) of test group were 10.0 and 15.0 months;and the mTTP and mOS of control group were 14.0 and 19.0 months, the difference were statistically significant (P=0.023 and P= 0.026). Tumor diameter ≥4.5 cm, numbers of tumor ≥3, invasion of blood vessels, α-fetoprotein≥200 μg/L, Eastern Cooperative Oncology Group score and diabetes were risk factors for OS of HCC patients. Conclusion Diabetes is unfavorable factors for overall survival of non-hepatitis HCC tread by TACE.
